Insight Molecular Diagnostics Inc. — Director's Dealing 2023

Apr 18, 2023

SEC Form 4/A — Form 4/A

Issuer: Oncocyte Corp (OCX)
CIK: 0001642380
Period of Report: 2023-03-06

Reporting Person: PURA VIDA INVESTMENTS, LLC (10% Owner)
Reporting Person: Kamen Efrem (10% Owner)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2023-03-06	Common Stock	J	3890111	—	Disposed	4589571	Indirect

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2023-03-06	Warrant to purchase common stock	$1.53	J	440964	Disposed	2027-04-19	Common Stock (440964)	Indirect

Holdings (Non-Derivative)

Security	Shares	Ownership
Common Stock	767952	Indirect
Common Stock	1381438	Indirect
Common Stock	7427202	Indirect

Holdings (Derivative)

Security	Exercise Price	Expiration	Underlying	Shares	Ownership
Warrant to purchase common stock	$1.53	2027-04-19	Common Stock (832949)	832949	Indirect
Warrant to purchase common stock	$1.53	2027-04-19	Common Stock (383976)	383976	Indirect
Warrant to purchase common stock	$1.53	2027-04-19	Common Stock (690719)	690719	Indirect

Footnotes

F1: As of March 6, 2023, the Reporting Persons no longer have voting and dispositive power for certain Managed Accounts and therefore such shares are no longer deemed beneficially owned by the Reporting Persons.

F2: Not applicable.

F3: Securities reported herein are owned by Pura Vida Master Fund, Ltd., Pura Vida X Fund LP, and Lockheed Martin Corporation Master Retirement Trust (the "Retirement Trust") and certain separately managed accounts (the "Managed Accounts" and collectively, the "Client Accounts"). Pura Vida Investments, LLC ("PVI") serves as the investment manager or sub-adviser to the Client Accounts. Efrem Kamen serves as the Managing Member of PVI.

F4: By virtue of these relationships, the Reporting Persons may be deemed to have shared voting and dispositive power with respect to the securities owned directly by the Client Accounts. This report shall not be deemed an admission that the Reporting Persons are beneficial owners of the securities for purposes of Sections 13 and 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein except to the extent of the Reporting Person's pecuniary interest therein, if any.

F5: As of March 6, 2023, the Reporting Persons no longer have voting and dispositive power for certain Managed Accounts and therefore the warrants and the underlying common stock are no longer deemed beneficially owned by the Reporting Persons.

F6: See footnotes 3 and 4.